51³ΙΘΛΆ―Βώ

Meeting Coverage

ASH Expert Roundtable: Follicular Lymphoma

Expert Roundtable from the American Society of Hematology

Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma

"Safety profile is one of the real advantages" of non-covalent BTK inhibitor, says panelist

image

Latest ASH Expert Roundtable: Follicular Lymphoma Meeting Coverage

Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma

Study results show impressive efficacy, favorable safety profile in the second line

January 4, 2024
Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma

Our panel of experts discuss 3-year findings from the phase II ELARA study

December 26, 2023
Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years

Bispecific antibody also shows high response rates in frontline setting

December 20, 2023
How Parsaclisib Compares to Other PI3K Inhibitors for Follicular Lymphoma

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

January 18, 2022
Tisagenlecleucel Promising in R/R Follicular Lymphoma

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

January 11, 2022
Lemzoparlimab Promising in Tough-to-Treat Lymphoma

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

December 28, 2021
Will Bispecific Antibodies Challenge CAR T-Cell Therapy in Follicular Lymphoma?

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

December 21, 2021

Latest Oncology/Hematology Meeting Coverage